AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Sep 2024 07:00 AM
RNS
Fasenra EGPA US FDA approval
13 Sep 2024 03:15 PM
RNS
Director/PDMR Shareholding
02 Sep 2024 03:00 PM
RNS
Total Voting Rights
16 Aug 2024 07:00 AM
RNS
Imfinzi approved in US for resectable lung cancer
01 Aug 2024 03:00 PM
RNS
Total Voting Rights
30 Jul 2024 07:00 AM
RNS
AstraZeneca prices a €1.4bn bond offering
29 Jul 2024 08:41 AM
RNS
Stabilisation Notice - ASTRAZENECA
29 Jul 2024 07:00 AM
RNS
Calquence fixed-duration combo improved 1L CLL PFS
26 Jul 2024 07:00 AM
RNS
ODAC reviewed Imfinzi in resectable lung cancer
25 Jul 2024 07:00 AM
RNS
Half-year Report
15 Jul 2024 07:00 AM
RNS
Acquisition of Amolyt Pharma completed
01 Jul 2024 03:00 PM
RNS
Total Voting Rights
01 Jul 2024 07:00 AM
RNS
Lynparza & Imfinzi positive CHMP in endometrial
25 Jun 2024 07:05 AM
RNS
Update on Imfinzi ADJUVANT BR.31 trial
25 Jun 2024 07:00 AM
RNS
Imfinzi improved EFS and OS in bladder cancer
18 Jun 2024 07:00 AM
RNS
Update on CAPItello-290 Phase III trial
17 Jun 2024 07:00 AM
RNS
Imfinzi approved in the US for endometrial cancer
12 Jun 2024 03:00 PM
RNS
Director/PDMR Shareholding
05 Jun 2024 07:00 AM
RNS
Acquisition of Fusion completed
03 Jun 2024 03:05 PM
RNS
Block listing Interim Review
03 Jun 2024 03:00 PM
RNS
Total Voting Rights
03 Jun 2024 07:00 AM
RNS
Tagrisso plus chemo recommended for approval in EU
28 May 2024 07:00 AM
RNS
Dato-DXd improved OS in nonsquamous lung cancer
21 May 2024 07:00 AM
RNS
AstraZeneca to deliver $80bn revenue by 2030
20 May 2024 07:00 AM
RNS
AstraZeneca to manufacture ADCs in Singapore
16 May 2024 07:00 AM
RNS
SUPERNOVA Trial Met COVID-19 prevention endpoint
15 May 2024 03:00 PM
RNS
Director/PDMR Shareholding
07 May 2024 07:00 AM
RNS
AstraZeneca completes Cellectis equity investment
02 May 2024 07:00 AM
RNS
Calquence combination improved PFS in 1L MCL
01 May 2024 03:00 PM
RNS
Total Voting Rights
29 Apr 2024 07:05 AM
RNS
Truqap recommended for EU breast cancer approval
29 Apr 2024 07:00 AM
RNS
Enhertu improved PFS in HER2-low and ultralow
25 Apr 2024 07:00 AM
RNS
1st Quarter Results
11 Apr 2024 05:30 PM
RNS
Result of AGM
11 Apr 2024 07:00 AM
RNS
AstraZeneca increases 2024 dividend by 7%
08 Apr 2024 07:00 AM
RNS
Enhertu approved in US for HER2+ solid tumours
05 Apr 2024 07:00 AM
RNS
Imfinzi improved OS & PFS in limited-stage SCLC
02 Apr 2024 03:00 PM
RNS
Total Voting Rights
02 Apr 2024 07:05 AM
RNS
Voydeya approved in US
02 Apr 2024 07:00 AM
RNS
FDA accepts Dato-DXd BLA for breast cancer
25 Mar 2024 07:00 AM
RNS
Ultomiris approved in the US for NMOSD
19 Mar 2024 07:00 AM
RNS
AstraZeneca to acquire Fusion
14 Mar 2024 07:00 AM
RNS
AstraZeneca to acquire Amolyt
12 Mar 2024 11:00 AM
RNS
Director/PDMR Shareholding
07 Mar 2024 11:00 AM
RNS
Notice of AGM
06 Mar 2024 03:05 PM
RNS
Director/PDMR Shareholding
06 Mar 2024 03:00 PM
RNS
Director/PDMR Shareholding
04 Mar 2024 07:00 AM
RNS
EMA validates Dato-DXd MAAs for NSQ NSCLC and BC
01 Mar 2024 03:00 PM
RNS
Total Voting Rights
26 Feb 2024 07:00 AM
RNS
Voydeya recommended for EU approval

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings